Patient summary
| UPN . | Dose level (mCi/kg) . | Age at HCT . | Frontline status . | Prior lines . | Disease status at HCT . | Risk factors . | Response after HCT . | CD25 expression score . | Current status . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.3 | 60 | Primary ref | 2 | PD | 3 | PR | RS: 0 Lymph: 2 | Relapsed at day +100, still alive ∼5 y after HCT |
| 2 | 0.3 | 24 | Primary ref | 2 | CR | 1 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 3 | 0.3 | 37 | Primary ref | 3 | PR | 4 | CR | RS: 2 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 4 | 0.4 | 35 | Primary ref | 3 | CR | 2 | CR | RS: NA Lymph: NA | Alive without relapse ∼5 y after HCT |
| 5 | 0.4 | 60 | Primary ref | 2 | CR | 2 | CR | RS: 2 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 6 | 0.4 | 40 | Early relapse | 2 | CR | 1 | CR | RS: 2 Lymph: 1 | Alive without relapse ∼5 y after HCT |
| 7 | 0.4 | 42 | Early relapse | 2 | CR | 1 | CR | RS: 1 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 8 | 0.4 | 32 | Primary ref | 3 | CR | 3 | CR | RS: 1 Lymph: 2 | Relapsed at day +144, died of HL ∼2 y after HCT |
| 9 | 0.4 | 32 | Primary ref | 3 | PR | 4 | CR | RS: 1 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 10 | 0.4 | 28 | Primary ref | 2 | CR | 2 | CR | RS: 2 Lymph: 1 | Alive without relapse ∼5 y after HCT |
| 11 | 0.4 | 26 | Primary ref | 2 | PR | 2 | CR | RS: 2 Lymph: 1 | Alive without relapse ∼5 y after HCT |
| 12 | 0.4 | 19 | Primary ref | 3 | CR | 3 | CR | RS: 0 Lymph: 2 | Post-HCT radiation, Relapsed at day +90, still alive ∼5 y after HCT |
| 13 | 0.4 | 33 | Early relapse | 2 | CR | 1 | CR | RS: 0 Lymph: 2 | Relapsed at day +262, still alive ∼5 y after HCT |
| 14 | 0.5 | 24 | Early relapse | 2 | CR | 2 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 15 | 0.5 | 38 | Primary ref | 3 | CR | 2 | CR | RS: NA Lymph: NA | Alive without relapse ∼3.5 y after HCT |
| 16 | 0.5 | 32 | Primary ref | 3 | PR | 3 | CR | RS: 1 Lymph: 2 | Relapsed at day +114, still alive ∼3 y after HCT |
| 17 | 0.6 | 42 | Early relapse | 2 | CR | 1 | CR | RS: 1 Lymph: 2 | Alive without relapse ∼3.5 y after HCT |
| 18 | 0.6 | 40 | Early relapse | 2 | CR | 2 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼3.5 y after HCT |
| 19 | 0.6 | 21 | Primary ref | 2 | CR | 2 | CR | RS: NA Lymph: NA | Relapsed at day +345, still alive ∼3 y after HCT |
| 20 | 0.6 | 22 | Primary ref | 2 | PR | 2 | PR | RS: 2 Lymph: 1 | Relapsed at day +81, still alive ∼3 y after HCT |
| 21 | 0.6 | 49 | Primary ref | 3 | CR | 2 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼2 y after HCT |
| 22 | 0.6 | 44 | Early relapse | 3 | CR | 3 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼1.5 y after HCT |
| UPN . | Dose level (mCi/kg) . | Age at HCT . | Frontline status . | Prior lines . | Disease status at HCT . | Risk factors . | Response after HCT . | CD25 expression score . | Current status . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.3 | 60 | Primary ref | 2 | PD | 3 | PR | RS: 0 Lymph: 2 | Relapsed at day +100, still alive ∼5 y after HCT |
| 2 | 0.3 | 24 | Primary ref | 2 | CR | 1 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 3 | 0.3 | 37 | Primary ref | 3 | PR | 4 | CR | RS: 2 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 4 | 0.4 | 35 | Primary ref | 3 | CR | 2 | CR | RS: NA Lymph: NA | Alive without relapse ∼5 y after HCT |
| 5 | 0.4 | 60 | Primary ref | 2 | CR | 2 | CR | RS: 2 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 6 | 0.4 | 40 | Early relapse | 2 | CR | 1 | CR | RS: 2 Lymph: 1 | Alive without relapse ∼5 y after HCT |
| 7 | 0.4 | 42 | Early relapse | 2 | CR | 1 | CR | RS: 1 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 8 | 0.4 | 32 | Primary ref | 3 | CR | 3 | CR | RS: 1 Lymph: 2 | Relapsed at day +144, died of HL ∼2 y after HCT |
| 9 | 0.4 | 32 | Primary ref | 3 | PR | 4 | CR | RS: 1 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 10 | 0.4 | 28 | Primary ref | 2 | CR | 2 | CR | RS: 2 Lymph: 1 | Alive without relapse ∼5 y after HCT |
| 11 | 0.4 | 26 | Primary ref | 2 | PR | 2 | CR | RS: 2 Lymph: 1 | Alive without relapse ∼5 y after HCT |
| 12 | 0.4 | 19 | Primary ref | 3 | CR | 3 | CR | RS: 0 Lymph: 2 | Post-HCT radiation, Relapsed at day +90, still alive ∼5 y after HCT |
| 13 | 0.4 | 33 | Early relapse | 2 | CR | 1 | CR | RS: 0 Lymph: 2 | Relapsed at day +262, still alive ∼5 y after HCT |
| 14 | 0.5 | 24 | Early relapse | 2 | CR | 2 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼5 y after HCT |
| 15 | 0.5 | 38 | Primary ref | 3 | CR | 2 | CR | RS: NA Lymph: NA | Alive without relapse ∼3.5 y after HCT |
| 16 | 0.5 | 32 | Primary ref | 3 | PR | 3 | CR | RS: 1 Lymph: 2 | Relapsed at day +114, still alive ∼3 y after HCT |
| 17 | 0.6 | 42 | Early relapse | 2 | CR | 1 | CR | RS: 1 Lymph: 2 | Alive without relapse ∼3.5 y after HCT |
| 18 | 0.6 | 40 | Early relapse | 2 | CR | 2 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼3.5 y after HCT |
| 19 | 0.6 | 21 | Primary ref | 2 | CR | 2 | CR | RS: NA Lymph: NA | Relapsed at day +345, still alive ∼3 y after HCT |
| 20 | 0.6 | 22 | Primary ref | 2 | PR | 2 | PR | RS: 2 Lymph: 1 | Relapsed at day +81, still alive ∼3 y after HCT |
| 21 | 0.6 | 49 | Primary ref | 3 | CR | 2 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼2 y after HCT |
| 22 | 0.6 | 44 | Early relapse | 3 | CR | 3 | CR | RS: 0 Lymph: 2 | Alive without relapse ∼1.5 y after HCT |
CR, complete response; Lymph, lymphocytes; PD, progressive disease; PR, partial response; Primary ref, primary refractory; SD, stable disease; UPN, unique patient number.